Co-Amoxiclav Preparation and Dosing
Co-amoxiclav (amoxicillin/clavulanic acid) is dosed based on the amoxicillin component, with standard adult dosing of 875 mg/125 mg orally twice daily or 500 mg/125 mg three times daily, and pediatric dosing of 45-90 mg/kg/day (amoxicillin component) divided into 2-3 doses depending on infection severity and pathogen resistance patterns. 1, 2
Adult Dosing
Oral Formulations
- Standard infections: 500 mg/125 mg three times daily OR 875 mg/125 mg twice daily 1
- Severe infections or resistant pathogens: Up to 1750 mg/day (amoxicillin component) in divided doses every 8-12 hours 1
- H. pylori eradication:
- Triple therapy: 1 gram amoxicillin (with 500 mg clarithromycin and 30 mg lansoprazole) twice daily for 14 days
- Dual therapy: 1 gram amoxicillin (with 30 mg lansoprazole) three times daily for 14 days 1
Intravenous Formulations
- Standard dosing: 1.2 grams IV every 8 hours 3, 4
- Early switch strategy: Begin with IV therapy for 3-4 days, then transition to oral formulation at equivalent dosing when clinically stable 3, 4
The evidence strongly supports early IV-to-oral switch therapy, with studies demonstrating comparable clinical efficacy (69% complete resolution) while reducing hospitalization duration from 10.21 to 4.12 days 3. This approach maintains therapeutic effectiveness while minimizing adverse effects of prolonged parenteral therapy.
Pediatric Dosing
Standard Dosing by Age
- Neonates and infants ≤3 months: Maximum 30 mg/kg/day divided every 12 hours 1
- Children >3 months: 20-45 mg/kg/day (amoxicillin component) divided every 8-12 hours 1
Infection-Specific Pediatric Dosing
For β-lactamase producing organisms (H. influenzae, M. catarrhalis):
- Standard formulation (4:1 ratio): 45 mg/kg/day in 3 divided doses 5
- High-dose formulation (14:1 ratio): 90 mg/kg/day in 2 divided doses 5
The high-dose formulation (Augmentin ES-600: 600 mg amoxicillin/42.9 mg clavulanate per 5 mL) was specifically developed to address penicillin-resistant S. pneumoniae while maintaining the same daily clavulanate dose to minimize gastrointestinal side effects 6, 7. This formulation achieves adequate coverage for organisms with penicillin MICs up to 2 mg/L 7.
Critical Care Considerations
Post-cardiac surgery patients with augmented clearance:
- Require 4-hourly dosing (30-60 mg/kg every 4 hours) instead of standard 6-hourly dosing 8
- Exception: Patients on vasopressors have reduced clearance (by 1/3) and can use standard 6-hourly dosing 8
This is crucial because augmented renal clearance in critically ill children can result in subtherapeutic concentrations with standard dosing intervals, leading to treatment failure 8.
Formulation Ratios and Bioavailability
Available Ratios
- 4:1 ratio (original): Most common formulation
- 7:1 ratio: Intermediate formulation
- 14:1 ratio (high-dose pediatric): Provides increased amoxicillin while maintaining clavulanate dose 6, 7
Oral Bioavailability
- Neonates ≤10 days: 24.4% bioavailability 9
- Older infants and children: Higher bioavailability with maturation 9
The 4:1 ratio is preferred for neonatal oral regimens as higher ratios (>4:1) may result in inadequate clavulanate exposure to effectively inhibit β-lactamases 9.
Renal Dose Adjustment
Severe renal impairment (GFR <30 mL/min): Reduce dose and/or extend dosing interval 1
Common Pitfalls to Avoid
Underdosing in resistant infections: For penicillin-intermediate or resistant S. pneumoniae, standard dosing is insufficient—use high-dose formulations (90 mg/kg/day) 7
Ignoring augmented clearance: Critically ill children, particularly post-cardiac surgery without vasopressor support, require more frequent dosing (every 4 hours vs. every 6 hours) 8
Incorrect ratio selection in neonates: Using ratios >4:1 in neonates may provide inadequate β-lactamase inhibition despite adequate amoxicillin levels 9
Prolonged IV therapy: When patients are clinically stable, switch to oral therapy after 3-4 days to reduce complications and costs while maintaining efficacy 3, 4
Dosing by total drug weight: Always dose based on the amoxicillin component, not the combined weight of amoxicillin plus clavulanate 1, 2
Tolerability Profile
Co-amoxiclav demonstrates excellent tolerability with only 3.6% adverse event incidence in large pediatric postmarketing studies 7. The most common adverse effects are mild gastrointestinal disturbances, with diarrhea occurring less frequently with twice-daily versus three-times-daily dosing 7. The high-dose formulation shows similar tolerability to conventional formulations 7.